>>182487, >>182488, >>182489, >>182490, >>182491, >>182492, >>182493, >>182494, >>182495, >>182496, >>182497, >>182498, >>182499, >>182500, >>182501, >>182502, >>182503, >>182504, >>182505, >>182506, >>182507, >>182508, >>182509, >>182510, >>182511, >>182512, >>182513, >>182514, >>182515, >>182516, >>182517, >>182518, >>182519, >>182520, >>182521, >>182522, >>182523, >>182524, >>182525, >>182526, >>182527, >>182528, >>182529, >>182530, >>182531, >>182532, >>182533, >>182534, >>182535, >>182536, >>182537, >>182538, >>182539, >>182540, >>182541, >>182542, >>182543, >>182544, >>182545, >>182546, >>182547, >>182548, >>182549, >>182550, >>182551, >>182552, >>182553, >>182554, >>182555, >>182556, >>182557, >>182558, >>182559, >>182560, >>182561, >>182562, >>182563, >>182564, >>182565, >>182566, >>182567, >>182568, >>182569, >>182570, >>182571, >>182572, >>182573, >>182574, >>182575, >>182576, >>182577, >>182578, >>182579, >>182580, >>182581, >>182582, >>182583, >>182584, >>182585, >>182586, >>182587, >>182588, >>182589, >>182590, >>182591, >>182592, >>182593, >>182594, >>182595, >>182596, >>182597, >>182598, >>182599, >>182600, >>182601, >>182602, >>182603
Diabetes: modulates metabolic pathways, improves insulin sensitivity
Fatty liver (NASH, NAFLD) - reduces hepatic inflammation
Neuropathic Pain - reduces inflammation by inhibiting NF-kB, STAT3
alleviates pain and nerve damage
Rheumatoid Arthritis - inhibits NF-kB activation
reduces secretion of IL-6 and other inflammatory cytokines,
blocks migration and invasion of RA fibroblast-like synoviocytes.
Psoriasis - inhibits keratinocyte hyperproliferation and reduces inflammation by downregulation of STAT3, NF-kB.
Airway Diseases (Asthma, Cystic Fibrosis, COPD)
Niclosamide inhibits certain Ca-activated Cl channels involved in mucus hypersecretion & bronchoconstriction (reduces mucus production & secretion.
it blocks release of mucus and inflammatory mediators which reduces bronchoconstriction.
anti-fibrotic agent for lung fibrosis - Niclosamide downregulates expression of collagen proteins and inhibits pro-fibrotic cytokines.
Endometriosis - Niclosamide targets STAT3 and NF-kB, reduces proinflammatory cytokines and reduces endometriotic lesion growth.
ALS
In vivo experimentation involving two ALS mouse models demonstrated slowed disease progression, enhanced survival rates, and reduced motor neuron loss and muscle atrophy.
At the molecular level, niclosamide inhibited dysregulated pathways such as STAT3 and mTOR, reduced gliosis, and dampened inflammatory signaling